Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Loses Big in Snap Election, Many Health-Savvy Members Ousted
October 28, 2024
- MHLW Lists Up 78 Drug-Loss Assets, Asks Makers to Report Any Hurdles in Development
October 28, 2024
- No New Safety Concerns for COVID-19 Vaccines in Japan: Experts
October 28, 2024
- MHLW to Update List of “Stable Supply Medicines” Eyeing Expansion
October 25, 2024
- MHLW Announces Revisions to Conditional Approval Rules
October 25, 2024
- MHLW Outlines Envisaged Cases of Regulatory Submissions without Japanese Data, Covering Rare Disease Drugs
October 24, 2024
- Contribution to Drug Discovery Up for Discussion in Revising Core Hospital Criteria
October 24, 2024
- Marukawa Touts Importance of Drug Innovation in Lower House Campaign
October 24, 2024
- LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
- Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
- ITP Pediatric Dosage Approvals on Agenda of MHLW Panel for Oct. 31
October 18, 2024
- MHLW Panel to Review BeiGene’s 1st Drug Candidate in Japan and More on Oct. 30
October 17, 2024
- Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
- MHLW to Run Follow-Up Survey on Updated Commercial Guidelines, Solo Distribution
October 15, 2024
- Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
- Japan’s Healthcare Spending Hits 46.7 Trillion Yen in FY2022
October 15, 2024
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
- MHLW Orders Label Revision for Systemic NSAIDs
October 11, 2024
- Xocova to Face CEA Price Cuts on Poor Cost Performance vs. SOC
October 10, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…